Wolters Kluwer Drug Pricing

October 17th, 2018 - Find-A-Code
Categories:   Drugs|Pharmaceuticals|FDA   Audits/Auditing   Practice Management   Medicaid   Medicare  
0 Votes - Sign in to vote or comment.

Wolters Kluwer provides unit and package pricing for multiple drug price types: Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC), Direct Price (DP), Manufacturer's Suggested Wholesale Price (SWP), Centers for Medicare & Medicaid Services, Federal Upper Limit (CMS FUL), Average Average Wholesale Price (AAWP), Generic Equivalent Average Price (GEAP).

Average Wholesale Price (AWP)

In the United States, the average wholesale price (AWP) is a pharmaceutical term that describes the average price paid by a retailer to buy a drug from the wholesaler. The AWP may be determined by several different methods.

  • The drug manufacturer may report the AWP to the individual publisher of drug pricing data
  • The AWP may also be calculated by the publisher based upon a mark-up specified by the manufacturer that is applied to the wholesale acquisition cost (WAC) or direct price (DP).
  • The wholesale acquisition cost (WAC) is the manufacturer’s list price of the drug when sold to the wholesaler. Pharmacies typically buy their drugs from wholesalers. WAC is the most common benchmark used today by pharmacies to buy drugs from wholesalers.
  • Typically a 20% mark-up is applied to the manufacturer-supplied WAC or DP, which results in the AWP.

Wholesale Acquisition Cost (WAC)

The wholesale acquisition cost (WAC) is an estimate of the manufacturer's list price for a drug to wholesalers or direct purchasers. WAC does not always represent the sales price in a single transaction accurately, as the manufacturer can choose to offer discounts or rebates that lower the price of which the product is sold to the wholesaler. 

Direct Price (DP)

Direct Price is the price at which non-wholesalers and providers can purchase drug products from a manufacturer. These prices can vary by transaction, as the manufacturer may offer discounts or rebates.

Manufacturer's Suggested Wholesale Price (SWP)

SWP is the reported price from the manufacturer for its drugs to be sold by wholesalers to customers. This does not reflect the pricing from the manufacturer to the customers. Wholesalers will determine the actual price of the product based on competitive and market factors.

Federal Upper Limit (CMS FUL)

The list of covered drug products comes directly from CMS and is updated periodically. They establish ceiling prices for each set of therapeutically equivalent drug products according to the formula in the Medicaid final regulation published July 31, 1987, by CMS' parent organization, the Department of Health and Human Services (HHS). The rule's reimbursement ceiling is set at 150% of the lowest published price for therapeutically equivalent drug products.

Average Wholesale Price (AAWP) & Generic Equivalent Average Price (GEAP)

The AAWP is a Wolters Kluwer Clinical Drug Information drug pricing concept. Generally, the AAWP represents the average of all AWPs for each multi-source drug product. The AAWP is not calculated when the number of manufacturers supplying a generic is insufficient. 

The Generic Equivalent Average Price (GEAP) is a Wolters Kluwer Clinical Drug Information drug pricing concept. The GEAP is not calculated when the number of manufacturers supplying a generic is insufficient. The GEAP is a generic price applied to all drug products sharing the same GPPC; however, all drug products with the same GPPC have not been used in the determination of the GEAP. 

To learn more, click here

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

​​Polysomnography Services Under OIG Scrutiny
September 2nd, 2021 - Raquel Shumway
The OIG conducted a study dated June 2019 wherein they indicated that there were approximately $269 million in overpayments for polysomnography services for the period of 2014 through 2015. According to the OIG “These errors occurred because the CMS oversight of polysomnography services was insufficient to ensure that providers complied with Medicare requirements and to prevent payment of claims that didn’t meet those requirements.” So what are those requirements?
Medicare Advantage - The Fastest Growing Government-Funded Program Undergoing Multiple Fraud Investigations
August 16th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Medicare Advantage is the fastest growing form of government-funded healthcare and the rate of fraud within this segment has come under increased scrutiny. Funding is determined by the health status of each beneficiary; therefore, accurate coding based on detailed documentation makes the medical record vital to the process because some ...
Billing Dental Implants under Medical Coverage
August 12th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
Implants can be costly to the patient and the provider, and it is crucial to understand how to bill a patient’s medical insurance to ensure there is adequate coverage for the best treatment. Implants are commonly billed in a dental office under a patient’s medical benefits.    Implants could be considered ...
New Codes for COVID Booster Vaccine & Monoclonal Antibody Products
August 10th, 2021 - Wyn Staheli, Director of Research
New codes have been announced for the COVID-19 booster vaccine, Novavax vaccine, and monoclonal antibody treatment.
Medicare's ABN Booklet Revised
July 29th, 2021 - Wyn Staheli, Director of Research
The “Medicare Advance Written Notices of Non-coverage” booklet, published by CMS’s Medicare Learning Network, was updated. This article discusses the changes to this booklet regarding the use of the ABN.
Chronic Pain Coding Today & in the Future
July 19th, 2021 - Wyn Staheli, Director of Research
Properly documenting and coding chronic pain can be challenging. As is commonly the case with many conditions, over the years, there has been a shift in the identification of different types of pain, including chronic pain. Understanding where we are now and where we are going will help your organization prepare for the future by changing documentation patterns now.
How Does Global and Professional Direct Contracting (GPDC) Affect Risk Adjustment?
July 15th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
CMS recently announced the 53 Direct Contracting Entities (DCEs) that will be participating in the April 1, 2021 through December 31, 2021 Global and Professional Direct Contracting (GPDC) Model. Among those participating is Clover Health Partners, who runs an in-home primary care program that has the potential to help Medicare ...



Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association